HR and breast carcinoma: Using age-matched control groups specific to breast cancer subtypes, our study revealed that patients with HR+/HER2− and HR−/HER2− breast cancer are significantly older at the time of their first breast cancer diagnosis than patients with HER2+ breast cancer and patients that were included in recent clinical studies.